Sedaghat Bita, Stephenson Rachel J, Giddam Ashwini Kumar, Eskandari Sharareh, Apte Simon H, Pattinson David J, Doolan Denise L, Toth Istvan
Infectious Diseases Program, QIMR Berghofer Medical Research Institute , Brisbane, Queensland 4029, Australia.
School of Pharmacy, The University of Queensland , Woolloongabba, Queensland 4012, Australia.
Bioconjug Chem. 2016 Mar 16;27(3):533-48. doi: 10.1021/acs.bioconjchem.5b00547. Epub 2016 Jan 25.
Present on the surface of antigen presenting cells (APCs), the mannose receptor (MR) has long been recognized as a front-line receptor in pathogen recognition. During the past decade many attempts have been made to target this receptor for applications including vaccine and drug development. In the present study, a library of vaccine constructs comprising fluorescently labeled mannosylated lipid-dendrimers that contained the ovalbumin CD4(+) epitope, OVA(323-339), as the model peptide antigen were synthesized using fluorenylmethyloxycarbonyl (Fmoc) solid phase peptide synthesis (SPPS). The vaccine constructs were designed with an alanine spacer between the O-linked mannose moieties to investigate the impact of distance between the mannose units on receptor-mediated uptake and/or binding in APCs. Uptake studies performed on F4/80(+) and CD11c(+) cells showed significant uptake and/or binding for lipopeptides containing mannose, and also the lipopeptide without mannose when compared to the control peptides (peptide with no lipid and peptide with no mannose and no lipid). Furthermore, mannan inhibition assays demonstrated that uptake of the mannosylated and lipidated peptides was receptor mediated. To address the specificity of receptor uptake, surface plasmon resonance studies were performed using biacore technology and confirmed high affinity of the mannosylated and lipidated vaccine constructs toward the MR. These studies confirm that both mannose and lipid moieties play significant roles in receptor-mediated uptake on APCs, potentially facilitating vaccine development.
甘露糖受体(MR)存在于抗原呈递细胞(APC)表面,长期以来一直被认为是病原体识别中的一线受体。在过去十年中,人们进行了许多尝试,将该受体用于包括疫苗和药物开发在内的应用。在本研究中,使用芴甲氧羰基(Fmoc)固相肽合成(SPPS)合成了一个疫苗构建体文库,该文库由荧光标记的甘露糖基化脂质树状大分子组成,其中包含卵清蛋白CD4(+)表位OVA(323 - 339)作为模型肽抗原。疫苗构建体在O-连接的甘露糖部分之间设计了一个丙氨酸间隔区,以研究甘露糖单元之间的距离对APC中受体介导的摄取和/或结合的影响。对F4/80(+)和CD11c(+)细胞进行的摄取研究表明,与对照肽(无脂质的肽以及无甘露糖和无脂质的肽)相比,含甘露糖的脂肽以及不含甘露糖的脂肽都有显著的摄取和/或结合。此外,甘露聚糖抑制试验表明,甘露糖基化和脂质化肽的摄取是受体介导的。为了研究受体摄取的特异性,使用生物传感器技术进行了表面等离子体共振研究,证实了甘露糖基化和脂质化疫苗构建体对MR具有高亲和力。这些研究证实,甘露糖和脂质部分在APC上受体介导的摄取中都起着重要作用,这可能有助于疫苗开发。